Traws Pharma, Inc. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
Traws Pharma, Inc. (TRAW) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of -$2.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-08-14
- Traws Pharma, Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$2.14M, a 2994.59% decline year-over-year.
- Traws Pharma, Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $50.00K.
- Traws Pharma, Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $2.71M, a 475.58% increase year-over-year.
- Traws Pharma, Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $189.00K.
- Traws Pharma, Inc. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2025 was $2.37M.
- Traws Pharma, Inc. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2024 was -$5.22M.
- Traws Pharma, Inc. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2023 was -$585.00K, a 170.65% decline from fiscal 2022.
- Traws Pharma, Inc. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2022 was $828.00K.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$2.09M 10-Q · filed 2026-08-14 | $619.00K derived: sum of 3 quarters · filed 2026-08-14 | $808.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $50.00K 10-Q · filed 2026-05-15 | $2.76M derived: sum of 2 quarters · filed 2026-05-15 | $2.95M derived: sum of 3 quarters · filed 2026-05-15 | $3.02M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $2.90M derived: sum of 2 quarters · filed 2026-04-15 | $2.97M derived: sum of 3 quarters · filed 2026-08-14 | $2.37M 10-K · filed 2026-04-15 |
| 2025-09-30 | $189.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $263.00K derived: sum of 2 quarters · filed 2026-08-14 | -$339.00K 10-Q · filed 2025-11-13 | $132.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$528.00K 10-Q · filed 2026-08-14 | -$57.00K derived: sum of 3 quarters · filed 2026-08-14 | -$916.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$602.00K 10-Q · filed 2026-05-15 | -$131.00K derived: sum of 2 quarters · filed 2026-05-15 | -$990.00K derived: sum of 3 quarters · filed 2026-05-15 | -$5.07M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $471.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$388.00K derived: sum of 2 quarters · filed 2026-04-15 | -$4.47M derived: sum of 3 quarters · filed 2026-04-15 | -$5.22M 10-K · filed 2026-04-15 |
| 2024-09-30 | -$859.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$4.94M derived: sum of 2 quarters · filed 2025-11-13 | -$5.69M 10-Q · filed 2025-11-13 | -$5.62M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$4.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$4.83M 10-Q · filed 2025-08-14 | -$4.76M derived: sum of 3 quarters · filed 2025-08-14 | -$4.83M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$747.00K 10-Q · filed 2025-05-15 | -$672.00K derived: sum of 2 quarters · filed 2025-05-15 | -$741.00K derived: sum of 3 quarters · filed 2025-05-15 | -$1.47M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $6.00K derived: sum of 2 quarters · filed 2025-03-31 | -$727.00K derived: sum of 3 quarters · filed 2025-03-31 | -$585.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$69.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$802.00K derived: sum of 2 quarters · filed 2024-11-14 | -$660.00K 10-Q · filed 2024-11-14 | -$50.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$733.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-15 | -$591.00K 10-Q · filed 2024-08-15 | $19.00K derived: sum of 3 quarters · filed 2024-08-15 | $138.00K derived: sum of 4 quarters · filed 2024-08-15 |
| 2023-03-31 | $142.00K 10-Q · filed 2024-05-15 | $752.00K derived: sum of 2 quarters · filed 2024-05-15 | $871.00K derived: sum of 3 quarters · filed 2024-05-15 | $1.50M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $610.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $729.00K derived: sum of 2 quarters · filed 2024-04-01 | $1.36M derived: sum of 3 quarters · filed 2024-04-01 | $828.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | $119.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $750.00K derived: sum of 2 quarters · filed 2023-11-14 | $218.00K 10-Q · filed 2023-11-14 | $601.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $631.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $99.00K 10-Q · filed 2023-08-14 | $482.00K derived: sum of 3 quarters · filed 2023-08-14 | $248.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$532.00K 10-Q · filed 2023-05-15 | -$149.00K derived: sum of 2 quarters · filed 2023-05-15 | -$383.00K derived: sum of 3 quarters · filed 2023-05-15 | -$512.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $383.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $149.00K derived: sum of 2 quarters · filed 2023-03-30 | $20.00K derived: sum of 3 quarters · filed 2023-03-30 | -$1.83M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$234.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$363.00K derived: sum of 2 quarters · filed 2022-11-14 | -$2.21M 10-Q · filed 2022-11-14 | -$590.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$129.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$1.98M 10-Q · filed 2022-08-15 | -$356.00K derived: sum of 3 quarters · filed 2022-08-15 | -$394.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$1.85M 10-Q · filed 2022-05-13 | -$227.00K derived: sum of 2 quarters · filed 2022-05-13 | -$265.00K derived: sum of 3 quarters · filed 2022-05-13 | $611.00K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $1.58M derived: sum of 2 quarters · filed 2022-03-21 | $2.46M derived: sum of 3 quarters · filed 2022-03-21 | $1.17M 10-K · filed 2022-03-21 |
| 2020-09-30 | -$38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $838.00K derived: sum of 2 quarters · filed 2021-11-15 | -$456.00K 10-Q · filed 2021-11-15 | -$109.00K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $876.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$418.00K 10-Q · filed 2021-08-16 | -$71.00K derived: sum of 3 quarters · filed 2021-08-16 | |
| 2020-03-31 | -$1.29M 10-Q · filed 2021-05-17 | -$947.00K derived: sum of 2 quarters · filed 2021-05-17 | ||
| 2019-12-31 | $347.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$378.00K 10-K · filed 2021-03-18 | ||
| 2019-09-30 | -$725.00K 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |